Evaluation of prognostic significance of hematological profiles after the intensive phase treatment in pulmonary tuberculosis patients from Romania

PLoS One. 2021 Apr 1;16(4):e0249301. doi: 10.1371/journal.pone.0249301. eCollection 2021.

Abstract

We evaluated in this cohort study the predictive ability of 23 peripheral blood parameters and ratios for treatment outcomes after the 2-month intensive phase in patients with PTB. In 63 patients out of 90 that turned culture negative, a significant decrease in white blood cell count, neutrophils, monocyte, hemoglobin, platelet, plateletcrit, erythrocyte sedimentation rate, MLR, NLR, PLR and SII values after anti-TB therapy compared to pretreatment was observed (p <0.001). Logistic regression analysis generated a model of predictors consisting of nine covariates. Spearman's correlation analysis revealed significant positive correlations between NLR with NEU (r = 0.79, p<0.01), SII with NEU (r = 0.846, p<0.01), PLT with SII (r = 0.831, p<0.01), PLT with PCT (r = 0.71, p<0.01) and MPV with P-LCR (r = 0,897, p<0.01) in 63 patients out of 90 that turned culture negative after 2 months of treatment. ROC curve analysis indicated that all areas under the curve (AUC) revealed no statistically significant results, except lymphocyte for culture conversion. In summary, here we observed a set of hematological parameters that declined significantly as the disease was treated in patients that turned culture negative. Despite some limitations, our findings are useful for further studies aiming to identify hematological profiles that could predict the treatment outcome.

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use
  • Area Under Curve
  • Blood Cell Count*
  • Blood Platelets / cytology
  • Female
  • Hematocrit*
  • Humans
  • Logistic Models
  • Lymphocytes / cytology
  • Male
  • Middle Aged
  • Neutrophils / cytology
  • Prognosis
  • ROC Curve
  • Retrospective Studies
  • Romania
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / pathology*

Substances

  • Antitubercular Agents

Grants and funding

The author(s) received no specific funding for this work.